To treat moderate-to-severe Alzheimer's
(donepezil HCl)
Please Help Support Alzheimer's Research Today!
Your Alzheimer's donation will help billions live without it.
According to the Alzheimer's Association, about 3.6 million Americans age 65 and older have moderate-to-severe Alzheimer's disease (AD), which is a degenerative disease of the brain that gets worse over time. By 2050, this number is expected to nearly triple to 10.4 million.
With the growing aging population, it is important to develop treatments that may help patients and their families living with this devastating condition. The U.S. Food and Drug Administration (FDA) recently approved a new once-daily, higher dose Aricept (R)(donepezil HCl) 23 mg tablet, offering a new dosing option for patients with moderate-to-severe AD. In the study of patients with moderate-to-severe AD, cognition was significantly improved in patients taking the Aricept 23 mg tablet versus those taking the Aricept 10 mg tablet, whereas global functioning was not.
"Slowing the decline of cognitive symptoms is important at all stages of Alzheimer's disease," said Dr. Martin R. Farlow, lead author of the study publication and professor and vice-chairman of research in Indiana University School of Medicine's Department of Neurology. "Throughout the course of Alzheimer's disease, caregivers are usually the first to notice changes in cognition. When a loved one notices the disease has gotten worse, it is important that they speak with a doctor about these changes and consider other treatments." Read more: mynews3.com
With the growing aging population, it is important to develop treatments that may help patients and their families living with this devastating condition. The U.S. Food and Drug Administration (FDA) recently approved a new once-daily, higher dose Aricept (R)(donepezil HCl) 23 mg tablet, offering a new dosing option for patients with moderate-to-severe AD. In the study of patients with moderate-to-severe AD, cognition was significantly improved in patients taking the Aricept 23 mg tablet versus those taking the Aricept 10 mg tablet, whereas global functioning was not.
"Slowing the decline of cognitive symptoms is important at all stages of Alzheimer's disease," said Dr. Martin R. Farlow, lead author of the study publication and professor and vice-chairman of research in Indiana University School of Medicine's Department of Neurology. "Throughout the course of Alzheimer's disease, caregivers are usually the first to notice changes in cognition. When a loved one notices the disease has gotten worse, it is important that they speak with a doctor about these changes and consider other treatments." Read more: mynews3.com
Anti-diabetic potential of lupin
The potential anti-diabetic activity of a glycoprotein found in lupin seeds may be due to its ability to pass through the gut barrier, where it may have bioactive properties – according to new research. Read more: nutraingredients.com
No comments:
Post a Comment